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Abstract
Purpose Intracranial lateral dural arteriovenous fistula (LDAVF) represents a specific subtype of cerebrovascular fistulae,
harboring a potentially life-threatening risk of brain hemorrhage. Fluoroscopically guided endovascular embolization is the
therapeutic gold standard. We provide detailed dosimetry data to suggest novel diagnostic reference levels (DRL).
Methods Retrospective single-center study of LDAVFs treated between January 2014 and December 2019. Regarding
dosimetry, the dose area product (DAP) and fluoroscopy time were analyzed for the following variables: Cognard scale
grade, endovascular technique, angiographic outcome, and digital subtraction angiography (DSA) protocol.
Results A total of 70 patients (19 female, median age 65 years) were included. Total median values for DAP and
fluoroscopy time were 325Gycm2 (25%/75% percentile: 245/414Gycm2) and 110min (68/142min), respectively. Nei-
ther median DAP nor fluoroscopy time were significantly different when comparing low-grade with high-grade LDAVF
(Cognard I+ IIa versus IIb–V; p> 0.05, each). Transvenous coil embolization yielded the lowest dosimetry values, with
significantly lower median values when compared to a combined transarterial/transvenous technique (DAP 290Gycm2 ver-
sus 388Gycm2, p= 0.031; fluoroscopy time 85min versus 170min, p= 0.016). A significant positive correlation was found
between number of arterial feeders treated by liquid embolization and both DAP (rs= 0.367; p= 0.010) and fluoroscopy
time (rs= 0.295; p= 0.040). Complete LDAVF occlusion was associated with transvenous coiling (p= 0.001). A low-dose
DSA protocol yielded a 20% reduction of DAP (p= 0.021).
Conclusion This LDAVF study suggests several local DRLs which varied substantially dependent on the endovascular
technique and DSA protocol.
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Introduction
Intracranial dural arteriovenous fistulae (DAVF) are patho-
logical shunts between meningeal arteries (i.e. fistula feed-
ers, which commonly arise from branches of the external
carotid artery) and intracranial venous sinus and/or cortical
veins, accounting for 10–15% of intracranial vascular mal-
formations [1]. The specific and relatively homogeneous
subgroup of lateral DAVF (LDAVF) is usually located at
the transverse and/or sigmoid sinus, is associated with sinus
thrombosis or head trauma involving the temporal bone and
commonly triggers pulsatile tinnitus [2, 3]. The LDAVFs
can be categorized according to the Cognard classification
into grades I–V [4], with a rising risk of intracranial hem-
orrhage in high-grade LDAVF (IIb–V) due to retrograde
filling of cortical veins with (IIb) or without (III–V) si-
nus involvement. In this context, even though patients with
a low-grade LDAVF (I or IIa) are not at risk of a bleeding,
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Fig. 1 Flowchart of the inclu-
sion and exclusion criteria.
CCF carotid-cavernous fistula,
DAVF dural arteriovenous fis-
tula, LDAVF lateral dural arteri-
ovenous fistula, TA transarterial,
TV transvenous
they commonly undergo treatment as the pulsatile tinnitus
may substantially reduce the quality of life [3].
Fluoroscopically guided endovascular embolization is
a standard first-line treatment in the field of intracranial
LDAVF [2, 3]. The choice of the endovascular technique,
e.g. transarterial liquid embolization with ethylene vinyl
alcohol copolymer (EVOH) and/or transvenous coil em-
bolization, strongly depends on the individual fistula mor-
phology, particularly with respect to the accessibility of
arterial fistula feeders and the type of venous drainage [2].
Since the national guidelines for radiation protection
have been updated in 2018 [5], diagnostic reference levels
(DRL) in endovascular procedures have gained increased
attention. To date, the German DRLs for neuroradiological
interventions are only defined for endovascular stroke and
aneurysm treatment [6]. Further fluoroscopically guided
neurointerventional procedures, such as embolization of
LDAVFs, are not yet established.
In recent years, several authors published dosimetry data
for neuroradiological interventions, including mechanical
thrombectomy in acute stroke as well as endovascular treat-
ment of intracranial aneurysms and arteriovenous malfor-
mations [7–16]; however, dosimetry data on the minimally
invasive embolization of intracranial DAVFs are sparse
[13–16]. Furthermore, these studies did not take the fistula
subgroups (particularly LDAVF), the Cognard grade or the
dedicated endovascular treatment technique (transarterial
and/or transvenous embolization) into consideration.
In this retrospective single-center study we report de-
tailed data on radiation dose and fluoroscopy time of en-
dovascular treatment for patients with LDAVFs, considering
the Cognard classification, endovascular technique, angio-
graphic outcome and applied digital subtraction angiogra-
phy (DSA) protocol. Our results may add valuable infor-
mation for the establishment of novel DRLs in the field on
intracranial DAVF treatment.
Methods
We retrospectively analyzed all consecutive patients with
a LDAVF who were endovascularly treated at our institution
between January 2014 and December 2019. The following
inclusion and exclusion criteria were defined (flowchart in
Fig. 1):
Inclusion criteria:
 Age ≥18 years
 Typical LDAVF located at the transverse and/or sig-
moid sinus, classified according to Cognard et al. into
grades I–V [4]
 Endovascular techniques: transarterial (TA) emboliza-
tion, transvenous (TV) embolization, combined
(TA+TV) treatment.
Exclusion criteria:
 Intracranial fistulae of other locations (carotid-cavernous
fistula, tentorial fistula, etc.)
 Multiple intracranial fistulae
 Second or more treatments in the same patient.
Endovascular procedures were performed with the pa-
tient under general anesthesia by 5 consultant interven-
tional neuroradiologists with at least 7 years and up to
over 20 years of experience in interventional neuroradiol-
ogy, using a biplane angiographic unit (Axiom Artis dBA,
Siemens Healthineers, Forchheim, Germany). The supra-
aortic arteries and sinus/veins were accessed using a trans-
femoral approach. The nonionic iodinated contrast agent
applied was Iomeprol 300mg iodine/ml (Imeron®, Bracco
Imaging Deutschland GmbH, Konstanz, Germany). The an-
giographic workflow comprised initial and final DSA acqui-
sitions including arterial and venous phase on standard an-
teroposterior and lateral projections with a preferred field of
view (FOV) of 32cm and a frame rate of 1–4 f/s. Peripro-
cedural DSA acquisitions were performed in arterial and
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early venous phase on working projections using a targeted
FOV of 11cm or 16cm and an increased frame rate of up
to 7.5 f/s for a sufficient visualization of the arteriovenous
shunt. The frame rate of pulsed fluoroscopy was 7.5 f/s.
With respect to the DSA acquisition type, two protocols
were preset by the manufacturer as previously reported [7]
and applied under discretion of the treating physicians:
 Low dose (LD): tube voltage 73kV, pulse width 50ms,
dose 1820µGy/pulse
 Normal dose (ND): tube voltage 73kV, pulse width
100ms, dose 3000µGy/pulse
Dosimetric Analysis
Imaging data and dose reports were retrieved from a dedi-
cated picture archiving and communication system (PACS,
Syngo Imaging, Siemens Healthineers) and reviewed by
two neuroradiologists with 10 (R.F.) and 11 (C.G.T.) years
of experience in interventional neuroradiology. The fol-
lowing parameters were recorded: LDAVF grades I–V ac-
cording to the Cognard classification, endovascular tech-
nique (TA, TV, combined TA/TV embolization), angio-
graphic outcome (complete versus incomplete occlusion,
i.e. LDAVF downgrading), DSA acquisition count, DSA
protocol (LD or ND), fluoroscopy time, and dose area prod-
uct (DAP) associated with fluoroscopy (DAPfluoroscopy) and
DSA (DAPDSA) acquisitions. The total DAP was calculated
by summing DAPfluoroscopy and DAPDSA. Dosimetry data were
recorded by summing values of both X-ray tubes.
Statistics
Continuous data are provided as median (25%; 75% in-
terquartile range), categorical data as counts and percent.
Data of DAP and fluoroscopy time among the groups of
Cognard grade, endovascular technique, angiographic out-
come, and DSA protocol were initially assessed for nor-
mality with the Kolmogorov-Smirnov test. Based on these
results we used pairwise nonparametric Mann-Whitney U-
tests to evaluate intergroup differences and applied Bon-
ferroni correction for multiple comparisons. Correlations
between the two variables number of treated feeders and
number of coils with radiation dose and fluoroscopy time
were examined with the Spearman rank correlation coeffi-
cient and the Pearson correlation coefficient, respectively.
Data analysis was performed using IBM SPSS Statistics for
Windows, Version 25.0 (IBM, Armonk, NY, USA). A level
of significance of p= 0.05 was used throughout the study.










Pulsatile tinnitus 60/65 (92.3)























13/49 (26.5%) 36/49 (73.5%)
TV coil embolization
(n= 14)
11/14 (78.6%) 3/14 (21.4%)
Combined (n= 7) 4/7 (57.1%) 3/7 (42.9%)
Baseline characteristics of 70 endovascularly treated patients with
LDAVF
LDAVF lateral dural arteriovenous fistula, ICH intracerebral




Baseline characteristics of endovascularly treated patients
with intracranial LDAVF are summarized in Table 1.
Within the study period, 70/113 (61.9%) patients with in-
tracranial DAVFs met the inclusion and exclusion criteria.
The median patient age was 65 years (range 25–80 years),
19/70 (27.1%) patients were women. Of the patients 65/70
(92.9%) underwent elective and 5/70 (7.1%) emergency
endovascular treatment of LDAVF. Regarding the lat-
ter group, four patients suffered from LDAVF-associated
intracranial hemorrhage (parenchymal bleeding, n= 3; sub-
arachnoid bleeding, n= 1) and one patient from acute onset
of trigeminal palsy accompanied by vertigo.
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With respect to the Cognard classification, 12/70 (17.1%)
patients presented with LDAVF grade I, 4/70 (5.7%) with
grade IIa, 17/70 (24.3%) with grade IIb, 10/70 (14.3%) with
grade III, 26/70 (37.1%) with grade IV, and 1/70 (1.4%)
with grade V.
Of the patients 49/70 (70.0%) underwent TA treatment
alone using a dedicated liquid embolic agent in each case
(EVOH: Onyx®, Medtronic, Dublin, Ireland or Squid®,
ab medica/Balt, Düsseldorf, Germany). In detail, 18/49
(36.7%) TA treated patients presented with a LDAVF Cog-
nard grade I–IIb, and 31/49 (63.3%) with grade III–V.
One arterial feeder was embolized in 26/49 (53.1%), two
feeders in 13/49 (26.5%), three feeders in 9/49 (18.4%),
and four feeders in 1/49 (2.0%) patients, 14/70 (20.0%)
patients underwent sole TV embolization using coils in
each case (median 15 coils; range 2–33 coils), including
3 patients with a LDAVF grades III–V, 7/70 (10.0%) pa-
Table 2 DAP and fluoroscopy time regarding the Cognard grade, endovascular technique, angiographic outcome, and DSA protocol in





























































TA vs. TV: p= 0.261
TA vs. Combined: p= 0.177
TV vs. Combined: p= 0.031






TA vs. TV: p= 0.372
TA vs. Combined: p= 0.078

































DAP and fluoroscopy time regarding the Cognard grade, endovascular technique, angiographic outcome, and DSA protocol in 70 minimally
invasive treated patients with LDAVF. DAP and FL time values are provided as median (25%; 75% percentile). Pair-wise comparison of DAP and
FL time with Bonferroni correction was performed using the Mann Whitney U-test. Significant values in bold
DAP dose area product, DSA digital subtraction angiography, FL fluoroscopy, LD low dose, LDAVF lateral dural arteriovenous fistula, ND normal
dose, TA transarterial, TV transvenous
tients were treated by a combination of TA liquid and TV
coil embolization.
After the intervention, 28/70 (40.0%) and 42/70 (60.0%)
LDAVFs were completely and incompletely occluded, re-
spectively. In detail, incomplete occlusion (i.e., downgrad-
ing) was documented in 9/16 (56.3%) low-grade (Cog-
nard I+ IIa) and 33/54 (61.1%) high-grade LDAVFs (Cog-
nard IIb–V, p= 0.776).
A significant association was found between the en-
dovascular technique and angiographic outcome according
to Fisher’s exact test (p= 0.001). In detail, TV coil em-
bolization more frequently yielded a complete occlusion of
LDAVF (n= 11/14, 78.6%) when compared to TA liquid
embolization (13/49, 26.5%).
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Radiation Dose and Fluoroscopy Time
Dosimetry results are presented in Table 2 and Figs. 2 and 3.
With respect to the entire study population (n= 70), the
median total DAP and fluoroscopy time were 325Gycm2
(245; 414Gycm2) and 110min (68; 142min), respectively.
With respect to the annual trend of radiation dose within
the study period, we observed a median total DAP of
491Gycm2 in 2014 (n= 9 patients), 260Gycm2 in 2015
(n= 9), 373Gycm2 in 2016 (n= 7), 287Gycm2 in 2017
(n= 19), 324Gycm2 in 2018 (n= 12), and 320Gycm2 in
2019 (n= 14).
The highest median dosimetry values were calculated for
LADVF Cognard grade III (DAP 184Gycm2; fluoroscopy
time 133min). When comparing low-grade (I+ IIa) with
high-grade LDAVF (IIb–V), median dosimetry values were
not significantly different (Fig. 2a: DAP, p= 0.386; Fig. 2b:
fluoroscopy time, p= 0.605).
With respect to the endovascular technique, the lowest
dosimetry values were observed for TV coil embolization.
In detail, both median total DAP and fluoroscopy time were
significantly lower when compared to a combined TA/TV
technique (Fig. 2c: DAP 290 versus 388Gycm2, p= 0.031;
Fig. 2 DAP and fluoroscopy time with respect to the Cognard classification (low-grade= I+ IIa, high-grade= IIb–V), different endovascular tech-
niques and angiographic outcome. Values shown as median (25%; 75% percentile). DAP dose area product
Fig. 2d: fluoroscopy time 85 versus 170min, p= 0.016).
Regarding TA liquid embolization (n= 49), we found a sig-
nificant positive correlation between the number of treated
arterial feeders and both DAP (rs= 0.367; p= 0.010) and
fluoroscopy time (rs= 0.295; p= 0.040). In patients treated
by TV coil embolization (n= 14), no significant associa-
tion was found between number of coils and the dosime-
try parameters (DAP: r= 0.463, p= 0.096; fluoroscopy time:
r= –0.362, p= 0.203).
Considering the angiographic outcome, median total
DAP and fluoroscopy time was 285Gycm2 and 82min for
patients with complete, and 371Gycm2 and 121min for
patients with incomplete occlusion of LDAVF (Fig. 2e,
p= 0.008 and Fig. 2f, p= 0.004, respectively).
Regarding the DSA acquisition type, a LD and ND pro-
tocol was applied in 45/70 (64.3%) and 25/70 (35.7%)
patients, respectively, yielding a significantly lower me-
dian total DAP in the former group (Fig. 3a; 315 versus
393Gycm2, p= 0.021). In detail, median values of DAPDSA
and DAPfluoroscopy were 230 and 85Gycm2 for the LD group
as well as 325 and 68Gycm2 for the ND group. Median
FL time was statistically equal between groups (Fig. 3b;
p= 0.611). Independent of the endovascular technique, the
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Fig. 3 Impact of the DSA protocol on DAP and fluoroscopy time, and association with the endovascular technique. a LD protocol yielded a signif-
icantly lower DAP when compared to a ND protocol (a; p= 0.021), while the median fluoroscopy time was statistically equal between groups (b;
p= 0.611). The interventional neuroradiologists preferentially decided for the LD protocol independent of the endovascular technique (c). DAP dose
area product, DSA digital subtraction angiography, LD low-dose, ND normal-dose
treating physicians preferentially decided for the LD pro-
tocol (Fig. 3c; TA: n= 29/49, 59.2%; TV: 10/14, 71.4%;
combined: 6/7, 85.7%).
The number of DSA acquisitions was not significantly
different between groups (Cognard grade, endovascular
technique, angiographic outcome, DSA protocol: p 0.05,
each).
Discussion
This retrospective single-center study provides detailed
dosimetry data for the endovascular treatment of intracra-
nial LDAVF in 70 patients between 2014 and 2019. In
particular, we believe that the strict selection criteria (e.g.,
exclusion of other intracranial fistulae, such as carotid-
cavernous fistula [17] or anterior cranial fossa DAVF [18])
as well as the dedicated consideration of both the Cognard
grade and endovascular technique (TA liquid embolization
with EVOH and/or TV coil embolization) is unique and
may therefore be valuable in order to introduce novel DRLs
in the field of interventional neuroradiology considering the
paramount impact of the Euratom Basic Safety Standards
directive [19].
For establishment of DRLs, which are defined as the
3rd quartile of the distribution of the DRL quantity, the In-
ternational Commission on Radiological Protection (ICRP)
135 publication requires utilization of several dosimetry
parameters such as DAP and fluoroscopy time [20]. As
a consequence, the 3rd quartile of DAP, which represents
a subsidiary dimension for X-ray energy delivered to the
patient [21], is commonly reported in neurointerventional
studies [7–15]. In the present study, the median DAP and
fluoroscopy time of the whole study population (n= 70)
was 325Gycm2 and 110min with a 3rd quartile value of
414Gycm2 and 142min, respectively. Regarding the liter-
ature, to date merely few neurointerventional studies re-
ported dosimetry values for intracranial DAVF treatment
[13–16]. The median DAP in these studies ranged between
150 and 360Gycm2; in addition, the 3rd quartile either
clearly exceeded our measured values (e.g., Kien et al.
726Gycm2) [14] or was not reported at all [16]. More-
over, the aforementioned studies neither yielded informa-
tion concerning the dedicated type of intracranial DAVF
nor the applied endovascular approach.
In this study, when subdividing the study cohort into low-
grade and high-grade LDAVFs, both median DAP and fluo-
roscopy time were statistically equal between groups. These
results suggest that dosimetry in endovascular LDAVF treat-
ment may be independent of the Cognard grade. Instead,
according to our data the endovascular technique signifi-
cantly influences the radiation dose. In detail, we calcu-
lated significantly lower median values for LDAVF patients
treated by TV coil embolization when compared to a com-
bined TA/TV treatment (DAP 290 versus 388Gycm2; flu-
oroscopy time 85 versus 170min). Also, the median val-
ues were lower in the TV coiling group when compared to
TA liquid embolization (DAP 329Gycm2, fluoroscopy time
111min), even though these differences did not reach sta-
tistical significance. Moreover, TV coil embolization com-
monly yielded a complete LDAVF occlusion, which in turn
resulted in significantly lower median values when com-
pared to patients in whom the fistula was not completely
occluded (DAP 285 versus 371Gycm2; fluoroscopy time 82
versus 121min).
In general, a comparably lower radiation dose in TV coil
embolization is reasonable when envisioning the procedural
workflow of endovascular LDAVF treatment. In Cognard
grades I–IIb fistulae, TV access to the transverse and/or
sigmoid sinus with subsequent therapeutic coil occlusion
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of the fistula-harboring sinus segment is commonly tech-
nically less sophisticated and succeeds more quickly when
compared to the superselective catheterization of one or
more arterial fistula feeders and time-consuming fluoro-
scopically-guided EVOH injection, except in the case of
a highly stenotic and/or compartmentalized sinus [22, 23].
The significantly positive correlation between the number of
arterial feeders treated by liquid embolization and both DAP
and fluoroscopy time measured in this study underlines this
statement. In contrast, the number of transvenously applied
coils had no significant effects on radiation doses.
However, due to the nature of LDAVF the choice of
the respective endovascular treatment is dependent on sev-
eral morphologic and hemodynamic factors, such as amount
and superselective accessibility of arterial feeders, the Cog-
nard grade (sinus involvement only in grades I–IIb), pa-
tency of the respective sinus segment, and kind of venous
filling (e.g., antegrade or retrograde flow within the vein
of Labbé) [22]. For example, TV coil occlusion of a still
patent fistula-harboring sinus segment alone is frequently
not possible, since the subsequent hemodynamic alterations
may yield hazardous venous congestion possibly resulting
in intracranial hemorrhage. As a consequence, LDAVFs
are commonly primarily treated via TA liquid embolization
whenever technically feasible [2, 22–26]. Available embolic
agents include particles, coils, ethanol, N-butyl cyanoacry-
late glue, and EVOH [22]. In this study, exclusively EVOH
(Onyx® or Squid®) was used for TA LDAVF embolization,
as previously published EVOH data suggested higher cure
rates when compared to alternative embolic agents [22, 24,
26]. With respect to the angiographic outcome, LDAVFs
embolized by TA access were downgraded in the majority
of cases in comparison to a definitive occlusion in most pa-
tients undergoing TV coil embolization, which was clearly
in the range of previously reported data [2, 27, 28].
Regarding radiation dose optimization in the field of in-
terventional neuroradiology, several techniques have been
proposed in recent years [7, 8, 12, 16, 29] in order to reduce
the potential risk of deterministic radiation effects partic-
ularly when considering complex and time-consuming in-
terventions and/or the necessity of multiple sessions [25,
26]. In this study, a LD DSA protocol, which was predeter-
mined by the manufacturer, yielded a 20% reduction of the
median total DAP when compared to a ND protocol (315
versus 393Gycm2). Disregarding fluoroscopy, because it
was equal in both the LD and ND group, LD DSA mode
allowed a dose reduction of approximately 30% (median
230 versus 325Gycm2). The positive impact of this dedi-
cated DSA protocol on radiation dose was previously also
demonstrated by Forbrig et al. who reported a 43% reduc-
tion of DAP in endovascularly treated patients with un-
ruptured intracranial aneurysms [7]. Furthermore, van der
Marel et al. reported a 37.6% reduction of DAP in en-
dovascular treatment of intracranial DAVF when utilizing
another angiography system with a dedicated dose reduc-
tion platform, which was not yet installed at our institution
within the study period [16]; however, their sample size
was low (normal dose n= 7; low dose n= 3), thus gener-
alizability remains limited as intracranial DAVFs represent
a heterogeneous spectrum of cerebrovascular diseases. In
this context it is worth mentioning that according to the
as low as reasonably achievable (ALARA) principle the
maximum achievable dose reduction in DAVF treatment is
limited as a reduced tube output may in turn substantially
increase image noise, which can be hazardous particularly
during TA injection of liquid embolic agents.
The results of the present study have to be evaluated in
light of several limitations, as data were collected retrospec-
tively from one neurovascular center. First, only one angio-
graphic system from a single manufacturer (Axiom Artis,
Siemens Healthineers) was used for neuroradiological in-
terventions and data were only collected for the common
subgroup of intracranial lateral DAVF. Hence, our dosime-
try measurements can neither be generalized for other an-
giography suites, particularly those of the newest generation
which contain additional techniques, probably enabling fur-
ther reduction of radiation dose, nor the entire spectrum of
intracranial DAVFs. Second, angiographic protocol settings
were slightly variable (e.g., frame rate of DSA) depending
on the respective physicians’ preference. Third, the follow-
ing parameters were not collected: air kerma product and
peak skin dose measured by thermoluminescent dosime-
ters. Instead, we decided to analyze the DAP because it
is part of the automatically generated dose report. There-
fore, it is easily accessible for every operator and can be
used as a valid estimate for the applied radiation dose for
each individual patient. We are aware that the DAP is only
a surrogate parameter for the tube output and not equal
to the exact effective patient dose; however, in analogy
to the dose length product in computed tomography, the
DAP in angiography is a clinically established and well ac-
cepted dose indicator. Finally, data of potentially conducted
repeated/multiple sessions at other neurovascular sites (in
patients in whom the LDAVF was only downgraded but
not completely occluded) are missing, disabling report of
cumulative doses which might be associated with the re-
spective Cognard grade; however, we believe that our re-
sults may serve as a dosimetry baseline dataset in the field
of neurointerventional LDAVF treatment, since comparable
studies have not yet been published.
Conclusion
This study provides detailed dosimetry data for the en-
dovascular treatment of intracranial LDAVF, which may
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be substantial for definition of novel DRLs. The DAP and
fluoroscopy time were dependent on the endovascular tech-
nique, with the lowest values for TV coil embolization.
A higher number of arterial feeders treated by liquid em-
bolization (EVOH: Onyx®, Squid®) was associated with an
increased DAP and fluoroscopy time, whereas the number
of transvenously applied coils did not substantially alter ra-
diation dose. Complete LDAVF occlusion was associated
with TV coil embolization, thus yielding a lower DAP and
fluoroscopy time when compared to LDAVF downgrading.
A low-dose DSA protocol yielded a 20% reduction of radi-
ation dose. Apart from various subjective parameters (e.g.,
institutional preferences and preconditions), this technical
approach enables a significant dose reduction in interven-
tional neuroradiology without compromising the capabil-
ity of individual patient treatment. Prospective multicenter
studies are warranted, including evaluation of modern an-
giography suites with novel dose reduction techniques, al-
ternative DSA and fluoroscopy settings (e.g., reduced frame
rates), and collection of cumulative doses in patients under-
going multiple treatments.
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